Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells
Sumin Kang, Shannon Elf, Katherine Lythgoe, Taro Hitosugi, Jack Taunton, Wei Zhou, Li Xiong, Dongsheng Wang, Susan Muller, Songqing Fan, Shi-Yong Sun, Adam I. Marcus, Ting-Lei Gu, Roberto D. Polakiewicz, Zhuo (Georgia) Chen, Fadlo R. Khuri, Dong M. Shin, Jing Chen
Sumin Kang, Shannon Elf, Katherine Lythgoe, Taro Hitosugi, Jack Taunton, Wei Zhou, Li Xiong, Dongsheng Wang, Susan Muller, Songqing Fan, Shi-Yong Sun, Adam I. Marcus, Ting-Lei Gu, Roberto D. Polakiewicz, Zhuo (Georgia) Chen, Fadlo R. Khuri, Dong M. Shin, Jing Chen
View: Text | PDF
Research Article Oncology

p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells

  • Text
  • PDF
Abstract

Head and neck squamous cell carcinoma (HNSCC) is one of the most common types of human cancer and frequently metastasizes to LNs. Identifying metastasis-promoting factors is of immense clinical interest, as the prognosis for patients with even a single unilateral LN metastasis is extremely poor. Here, we report that p90 ribosomal S6 kinase 2 (RSK2) promotes human HNSCC cell invasion and metastasis. We determined that RSK2 was overexpressed and activated in highly invasive HNSCC cell lines compared with poorly invasive cell lines. Expression of RSK2 also correlated with metastatic progression in patients with HNSCC. Ectopic expression of RSK2 substantially enhanced the invasive capacity of HNSCC cells, while inhibition of RSK2 activity led to marked attenuation of invasion in vitro. Additionally, shRNA knockdown of RSK2 substantially reduced the invasive and metastatic potential of HNSCC cells in vitro and in vivo in a xenograft mouse model, respectively. Mechanistically, we determined that cAMP-responsive element-binding protein (CREB) and Hsp27 are phosphorylated and activated by RSK2 and are important for the RSK2-mediated invasive ability of HNSCC cells. Our findings suggest that RSK2 is involved in the prometastatic programming of HNSCC cells, through phosphorylation of proteins in a putative signaling network. Moreover, targeting RSK2 markedly attenuates in vitro invasion and in vivo metastasis of HNSCC cells, suggesting that RSK2 may represent a therapeutic target in the treatment of metastatic HNSCC.

Authors

Sumin Kang, Shannon Elf, Katherine Lythgoe, Taro Hitosugi, Jack Taunton, Wei Zhou, Li Xiong, Dongsheng Wang, Susan Muller, Songqing Fan, Shi-Yong Sun, Adam I. Marcus, Ting-Lei Gu, Roberto D. Polakiewicz, Zhuo (Georgia) Chen, Fadlo R. Khuri, Dong M. Shin, Jing Chen

×

Figure 6

RSK2 promotes HNSCC cell invasion through phosphorylation and activation of the downstream substrate CREB.

Options: View larger image (or click on image) Download as PowerPoint
RSK2 promotes HNSCC cell invasion through phosphorylation and activation...
(A) RNAi-mediated stable knockdown of CREB and Hsp27 in M4e cells. (B) Knockdown of CREB and Hsp27 significantly reduced the invasive ability of metastatic M4e cells. Relative invasion was normalized to the invasion of M4e-pLKO.1 cells (mean ± SD; *P = 0.01–0.05). (C) Stable knockdown of CREB and Hsp27 did not significantly affect the proliferation rate of M4e cells (mean ± SD). (D) Expression of RSK2 promoted invasive ability of Tu212 cells, whereas targeted downregulation of CREB significantly attenuated RSK2-dependent invasion. Relative invasion was normalized to the invasion of control Tu212 cells (mean ± SD; **P < 0.01). (E and F) Stable expression of the phospho-mimetic CREB S133D mutant but not the phospho-deficient S133A mutant, further significantly enhanced 686LN (E) and Tu212 (F) cell invasion, compared with CREB WT. Relative invasion was normalized to the invasion of control cells harboring an empty vector (mean ± SD; *P = 0.01–0.05).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts